ReviewNature reviews. Drug discovery2024
Targeting ROS in cancer: rationale and strategies.
Review in Nature reviews. Drug discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 298 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
298 citing papers in PubMed.
- Calcium overload induces reactive oxygen species to enhance glioblastoma radiosensitivity.Medical gas research · 2026Article
- Activatable NIR-II photoacoustic probes for cancer imaging and imaging-guided therapy.Bioactive materials · 2026Review
- Ionomycin enhances radiosensitivity in breast cancer through reactive oxygen species generation and mitochondrial permeability transition pore opening.Medical gas research · 2026Article
- Redox-mediated mitochondrial collapse drives intrinsic apoptotic signaling in ELT3 cells response to apigenin.Toxicology reports · 2026Article
- CPT-TCPP polymeric nanoplatform for sonodynamic-chemotherapy synergistic tumor therapy through ferroptosis-apoptosis dual cell death reprogramming.Materials today. Bio · 2026Article
- Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Article
- NR3C2 suppresses triple-negative breast cancer progression by regulating mitochondrial ROS homeostasis via NDUFB3.Translational oncology · 2026Article
- Advanced nanocatalytic medicine for genitourinary diseases: Reactive oxygen modulation, precision therapeutics, and clinical translation.Materials today. Bio · 2026Article
- Synergistic Anticancer Effects of Lenvatinib and Celastrol via Reactive Oxygen Species-Mediated Endoplasmic Reticulum Stress and JNK Signaling in Colon Cancer Cells.Cancer research and treatment · 2026Article
- Blood-Brain Barrier Regulation: Evolving From Classic Strategies to Electrochemical Ion and Reactive Oxygen Species Control.Advanced healthcare materials · 2026Review
- MMSDH facilitates ACSL4 propionylation to counteract ferroptosis upon hypoxia and impairs PDAC chemotherapy efficacy.Nature cancer · 2026Article
- Interplay Between Epigenetics and Reactive Oxygen Species in Tumor Radioresistance: Mechanisms and Therapeutic Strategies for Radiotherapy.Cancer medicine · 2026Review
- Stimuli-responsive structural transformation of adaptive peptide nanomaterials toward biomedical applications.Materials today. Bio · 2026Review
- Topological Quantum Biomaterials Enable Pyroptosis-Senescence Coupling for Enhanced Colorectal Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Ultrasound-activated CuJournal of nanobiotechnology · 2026Article
- Supramolecular Chiral Assemblies from Benzoselenadiazole-Alanine-Acylhydrazone Conjugates Enable Cardioprotection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Cold Atmospheric Plasma Reduces Migration and Viability of Oral Squamous Cell Carcinoma Cells and Increases E-Cadherin Expression.Current issues in molecular biology · 2026Article
- Serum Redox Biomarkers in Canine Mast Cell Tumors: Exploratory Associations with Proliferative Activity and Clinicopathological Features.Antioxidants (Basel, Switzerland) · 2026Article
238 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reactive oxygen species (ROS) in biological systems are transient but essential molecules that are generated and eliminated by a complex set of delicately balanced molecular machineries. Disruption of redox homeostasis has been associated with various human diseases, especially cancer, in which increased ROS levels are thought to have a major role in tumour development and progression. As such, modulation of cellular redox status by targeting ROS and their regulatory machineries is considered a promising therapeutic strategy for cancer treatment. Recently, there has been major progress in this field, including the discovery of novel redox signalling pathways that affect the metabolism of tumour cells as well as immune cells in the tumour microenvironment, and the intriguing ROS regulation of biomolecular phase separation. Progress has also been made in exploring redox regulation in cancer stem cells, the role of ROS in determining cell fate and new anticancer agents that target ROS. This Review discusses these research developments and their implications for cancer therapy and drug discovery, as well as emerging concepts, paradoxes and future perspectives.
Indexed as
Identifiers
38982305What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.